Anticancer drug screening with in vitro models

Drugs of the Future

Volumn 22, Issue 7, 1997, Pages 739-746

  Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CELL LINE; DRUG ACTIVATION; DRUG METABOLISM; DRUG SCREENING; HUMAN; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TUMOR CELL;

EID: 0030858845     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Workman, P. Emerging from a crisis in anticancer drug discovery? Screening versus design: Confessions of an optimistic fencesitter. Ann Oncol 1992, 3: 619-705.
2. Sikic, B.I. Anticancer drug discovery. J Natl Cancer Inst 1991, 83: 738-40.
3. Schacter, L. P., Anderson, C., Canetta, R.M. et al. Drug discovery and development in the pharmaceutical industry. Semin Oncol 1992, 19: 613-21.
4. Goldin, A., Venditti, J.M. Progress report on the screening program at the division of cancer treatment, National Cancer Institute. Cancer Treat Rev 1980, 7: 167-76.
5. Grever, M. R., Schepartz, S.A., Chabner, B.A. The National Cancer Institute cancer drug delivery and development program. Semin Oncol 1992, 19: 622-38.
6. Jonhson, R.K. Screening methods in antineoplastic drug discovery. J Natl Cancer Inst 1990, 82: 1082-3.
7. Chabner, B.A. In defense of cell-line screening. J Natl Cancer Inst 1990, 82: 1085-6.
8. Grindley, G.B. Current status of cancer drug development: Failure or limited success? Cancer Cells 1990, 2: 163-71.
9. Monks, A., Scudiero, D., Skehan, P. et al. Feasibility of high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83: 757-66.
10. Skehan, P., Storeng, R., Scudiero, D. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990, 82: 1107-12.
11. Boyd, M.R., Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Develop Res 1995, 34: 91-109.
12. Weinstein, J.N., Myers, T.G., O'Connor, P.M. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275: 343-9.
13. Paull, K.D., Shoemaker, R.H., Modes, L. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of a mean graph and COMPARE algorithm. J Natl Cancer Inst 1989, 81: 1088-92.
14. Leteurtre, F., Kohlhagen, G., Paull, K.D., Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP-937 and DuP-941 (losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst 1994, 86: 1239-44.
15. Cleaveland, E.S., Monks, A., Vaigro-Wolff, A. et al. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program. Biochem Pharmacol 1995, 49: 947-54.
16. Paull, K.D., Lin, C.M., Malspeis, L., Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992, 52: 3892-900.
17. Weisenthal, L., Dill, P., Birkhofer, M. Accurate identification of disease-specific activity of antineoplastic agents with an in vitro fresh tumor assay measuring killing of largely non-dividing cells. Proc Am Assoc Cancer Res 1991, 32: 2280.
18. Shoemaker, R.H., Wolpert-DeFilippes, M.K., Kern, D.H. et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985, 45: 2145-53.
19. Riebig, H.H., Schmid, J.R., Bieser, W., Henss, H., Löhr, G.W. Colony assay with human tumor xenograft, murine tumors and human bone marrow. Potential for anticancer drug development. Eur J Cancer Clin Oncol 1987, 23: 937-48.
20. Berger, D.P., Henss, H., Winterhalter, B.R., Fiebig, H.H. The clonogenic assay with human tumor xenografts: Evaluation, predictive value and application for drug screening. Ann Oncol 1990, 1: 333-41.
21. Weisenthal, L.M. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J Natl Cancer Inst 1992, 84: 466-9.
22. Corbett, T.H., Valeriote, F.A., Polin, L. et al. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion assay. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. F.A. Valeriote, T.H. Corbett, L.H. Baker (Eds.). Kluwer Academic Publishers: Boston 1992, 35-87.
23. Valeriote, F., Corbett, T., Edelstein, M., Baker, L. New in vitro screening for the discovery of antileukemic anticancer agents. Cancer Invest 1996, 14: 124-41
24. Devlin, J.J., Panganiban, L.C., Devlin, P.E. Random peptide libraries. A source of specific protein-binding molecule peptides from a hexapeptide epitope library. Science 1990, 249: 404-6.
25. Lam, K.S., Salmon, S.E., Hersch, E.M. et al. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991, 354, 82-4.
26. Houghten, R.A., Pinilla, C., Blondelle, S.E., Appel, H.J.R., Dooley, C.T., Cuervo, J.H. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 1991, 354: 84-6.
27. Salmon, S.E., Lam, K.S., Lebl, M. et al. Identification of biologically active peptides by random library testing in solution by orthogonal staged release following solid-phase peptide synthesis. Proc Natl Acad Sci USA 1993, 90: 11708-12.
28. Salmon, S.E., Lam, K.S., Felder, S. et al. One bead, one chemical compound: Use of the Selectide process for anticancer drug discovery. Acta Oncol 1994, 33: 127-31.
29. Schwartsmann, G., Workman, P. Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer 1993, 29: 3-14.
30. Endicott, J.A., Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989, 58: 137-71.
31. Pastan, I., Gottesman, M.M. Multidrug resistance. Annu Rev Med 1991, 42: 277-86.
32. Nielsen, D., Skovsgaard, T. P-glycoprotein as multidrug transporter, a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1992, 1139: 169-83.
33. Dhar, S., Nygren, P., Csoka, K., Botling, J., Nilsson, K., Larsson, R. Anticancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 1996, 74: 888-96.
34. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in respect to alkylating, carcinogenic and therapeutic agents. Cancer Res 1990, 50: 6119-29.
35. Swaffar, D.S., Ireland, C.M., Barrows, L.R. A rapid mechanism-based screen to detect potential anti-cancer agents. Anti-Cancer Drugs 1994, 5: 15-23.
36. Damia, G., Imperatori, L., Stefanini, M., D'Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. Int J Cancer 1996, 66: 779-83.
37. Workman, P., Stratford, I.J. The experimental development of bio-reductive drugs and their role in cancer therapy. Cancer Metastasis Rev 1993, 12: 73-82.
38. Nishiyama, M., Saeki, S., Hirabayashi, N., Toge, T. Relevance of DT-diaphorase activity to mitomycin C efficacy on human cancer cells. Differences in in vivo and in vitro systems. Int J Cancer 1993, 53: 1013-6.
39. Albin, N., Massaad, L., Toussaint, C. et al. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 1993, 53: 3541-6.
40. Goeptar, A.R., Tekoppele, J.M., Glatt, H.R. et al. The cytotoxicity of mitomycin C and adriamycin in genetically engineered V79 cells and freshly isolated hepatocytes. Chem Biol Interact 1995, 97: 149-68.
41. Pilot, H.C. The molecular biology of carcinogenesis. Cancer 1993, 72: 962-70.
42. Brunton, V.G., Workman, P. Cell signaling targets for antitumor drug development. Cancer Chemother Pharmacol 1993, 32: 1-19.
43. Powis, G. Signalling pathways as targets for anticancer drug development. Pharmacol Ther 1994, 62: 57-95.
44. Hurst, H.C. Transcription factors as drug targets in cancer. Eur J Cancer 1996, 32A: 1857-63.
45. James, G.L., Goldstein, J.L., Brown, M.S. et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 1993, 260: 1937-42.
46. Kohl, N.B., Mosser, S.D., de Solms, S.J. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260: 1934-7.
47. Jenkins, D.C., Stables, J.N., Wilkinson, J. et al. A novel cell-based assay for the evaluation of anti-ras compounds. Br J Cancer 1993, 68: 856-61.
48. Corbley, M.J., Cherington, V., Traxler, P.M., Lydon, N.B., Roberts, T.M. A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. Int J Cancer 1996, 66: 753-9.
49. Brown, R. P53: A target for new anticancer drugs or a target for old drugs? Ann Oncol 1993, 4: 623-9.
50. Fan, S., Smith, M.L., Rivet, D.J. et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55: 1649-54.
51. Sidransky, D. Molecular screening. How long can we afford to wait? J Natl Cancer Inst 1994, 86: 955-6.
52. Riou, J.F., Lefèvre, D., Riou G. Stimulation of the topoisomerase II-induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression. Biochemistry 1989, 28: 9104-10.
53. Chabner, B.A. Camptothecins. J Clin Oncol 1992, 10: 3-4.
54. Jansen, W.J.M., Zwart, B, Hulscher, S.T.M., Giaccone, G, Pinedo, H.M., Boven, E. CPT-11 in human colon cancer cell lines and xenografts: Characterization of cellular sensitivity determinants. Int J Cancer 1997, 70: 335-40.
55. Bates, S.E., Fojo, A.T., Weinstein, J.N. et al. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 1995, 121: 495-500.
56. Alvarez, M., Paull, K., Monks, A. et al. Generation of a drug-resistance profile by quantitation of MDR1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 1995, 95: 2205-14.
57. Neidle, S. Discovery of new anticancer drugs by computer-aided drug design. Ann Oncol 1994, 5: S51-4.
58. Gibbs, J.B.B., Oliff, A. Pharmaceutical research in molecular oncology. Cell 1994, 79: 193-8.
59. Gottesman, M.M. Molecular basis of cancer therapy. J Natl Cancer Inst 1994, 86: 1277-85.
60. Connors, T.A. Is there a future for cancer chemotherapy? Ann Oncol 1996, 7: 445-52.
61. Thomas, H., Balkwill, F.P. Oncogene transgenic mice as therapeutic models in cancer research. Eur J Cancer 1994, 30A: 533-7.
62. Viney, J.L. Transgenic and gene knockout mice in cancer research. Cancer Metastasis Rev 1995, 14: 77-90.